Abstract
The notion of achieving immune tolerance—and eliminating toxic antirejection drugs—in transplant patients is moving closer to reality, as reported in hundreds of abstracts presented at the American Transplant Congress, the joint meeting of the American Society of Transplant Surgeons and the American Transplant Society.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
